InspireMD, Inc. NSPR
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -60.90%
- 1 year
- -64.49%
- Market cap
- 32.36M
- Revenue (ttm)
- 6.82M
- EPS (ttm)
- -0.62
- Shares out
- 26.08M
- Forward P/E
- -4.15
- YTD return
- -60.90%
- 1-year return
- -64.49%
- Volume
- 342.67K
- Avg volume
- 166.84K
- Open
- 0.621
- Previous close
- 0.639
- Day's range
- 0.6099 – 0.7124
- 52-week range
- 0.43 – 2.22
- Analysts
- Strong Buy
- Price target
- 4.75 (+582.5%)
5D +0.2318 (+49.94%)
Key statistics
- Enterprise value
- 37.44M
- PEG ratio
- 0.00
- Price / sales
- 11.28
- Price / book
- 1.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 16.30%
- Free cash flow
- 0
- Total cash
- 40.40M
- Total debt
- 682.00K
- Return on equity
- -66.75%
- Short % of float
- 0.90%
- 50-day average
- 2.69
- 200-day average
- 2.57
Analyst view
Consensus: strong buy
- Target (low)
- 4.50
- Target (mean)
- 4.75
- Target (high)
- 5.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.195.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.20 | -0.16 | +0.04 | +20.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| May 14, 2024 | Mar 1, 2024 | -0.15 | -0.21 | -0.06 | -40.00% |
| Mar 6, 2024 | Dec 1, 2023 | -0.20 | -0.16 | +0.04 | +20.00% |
| Nov 6, 2023 | Sep 1, 2023 | -0.17 | -0.15 | +0.02 | +11.76% |
| Aug 8, 2023 | Jun 1, 2023 | -0.17 | -0.24 | -0.07 | -41.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Lake Street | init | — | Buy |
| Nov 2, 2023 | Piper Sandler | main | Overweight | Overweight |
| Jun 12, 2023 | Piper Sandler | init | — | Overweight |
| May 17, 2023 | National Alliance Securities | main | — | Buy |
| Mar 31, 2023 | Alliance Global Partners | main | — | Buy |
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- inspiremd.com
News
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Full Transcript: InspireMD Q2 2026 Earnings Call
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Dell Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 
InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate 
InspireMD Announces 30-Day Outcomes From CGUARDIANS II Clinical Trial Of CGuard Prime 80cm Implant For Use In Transcarotid Artery Revascularization Procedures - InspireMD Announces First Patient Enrolled In CGUARDIANS III Pivotal Study Of SwitchGuard Neuro Protection System, For Use With CGuard Prime 80 cm Stent Platform, In TCAR Procedures
Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3 - Transcript: InspireMD Q1 2026 Earnings Conference Call
Your note
Sign in to keep a note on NSPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD KATHRYN | Director | Stock Award(Grant) | Jan 22, 2024 | 215,040 |
| BERMAN MICHAEL | Director | Conversion of Exercise of derivative security | Jun 23, 2024 | 0 |
| GLEASON SHANE THOMAS | Officer | Stock Award(Grant) | Jan 22, 2024 | 514,365 |
| KESTER THOMAS J | Director | Conversion of Exercise of derivative security | May 27, 2024 | 326,652 |
| ROUBIN GARY S | Director | Conversion of Exercise of derivative security | May 27, 2024 | 501,788 |
| SHORE CRAIG | Chief Financial Officer | Stock Award(Grant) | Jan 22, 2024 | 879,844 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 9.64% | 2,514,046 | 7.42M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 8.47% | 2,209,593 | 6.52M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 8.18% | 2,133,405 | 6.29M | Sep 29, 2024 |
| Marshall Wace LLP | 7.13% | 1,860,405 | 5.49M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 5.28% | 1,378,128 | 4.07M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 3.47% | 904,029 | 2.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 18,244 | 53.82K | Oct 30, 2024 |